Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2024-08-12 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
52-109F2 - Certification of interim filings - CEO (F).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CFO of Theralase Technologies Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2024. The document is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, including controls over financial reporting. It does not contain the actual interim financial statements or substantive financial data itself, but rather attests to their validity. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself. The document length is 3227 characters, which is relatively short and consistent with a certification letter rather than a full interim report. Therefore, the correct classification is Regulatory Filings (RNS).
2024-08-12 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CEO, certifying the accuracy and fairness of the interim financial report and interim MD&A for the period ended June 30, 2024. It is primarily an officer certification letter confirming the integrity of the interim filings rather than the filings themselves. The document length is short (3260 characters) and contains no actual financial data or analysis, only certification statements. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself.
2024-08-12 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Condensed Interim Consolidated Financial Statements As at June 30, 2024 and for six-month period ended June 30, 2024 and 2023'. It contains detailed financial statements including Consolidated Statements of Financial Position, Operations, Cash Flows, and Changes in Equity for the six-month period ended June 30, 2024. The document references compliance with IAS 34 'Interim Financial Reporting' and IFRS standards, indicating it is an interim financial report. The document is approximately 15,000 characters long, which is substantial and contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-12 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management's Discussion and Analysis of Financial Condition and Operations' (MD&A) for Theralase Technologies Inc. It references unaudited condensed consolidated interim financial statements for the six-month period ended June 30, 2024, indicating it covers a half-year period. The content includes detailed discussion of business operations, clinical studies, financing activities, and forward-looking statements. The length is substantial (15,000 characters), and it contains substantive financial and operational analysis rather than just an announcement or certification. The MD&A is a management report explaining financial results and business trends for an interim period, consistent with the definition of an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-12 English
News release - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a press release from Theralase Technologies Inc. dated August 12, 2024, announcing the release of their unaudited condensed consolidated interim financial statements for the six-month period ended June 30, 2024. It includes detailed financial data such as revenue, cost of sales, gross margin, operating expenses, and net loss for the period. Additionally, it provides operational highlights, clinical study updates, and information about private placements and funding plans. The presence of detailed interim financial statements and operational data for a period shorter than a full fiscal year, along with the explicit mention of 'interim financial statements' and the six-month period ended June 30, 2024, clearly identifies this document as an Interim / Quarterly Report. It is not merely an announcement or a summary but contains substantive financial data and analysis. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). H1 2024
2024-08-12 English
Report of exempt distribution (45-106F1) (amended).pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution, including issuer details, distribution dates, purchaser information, types of securities distributed, compensation information, and details about directors and officers. This form is a regulatory filing used in Canada to report exempt distributions of securities under National Instrument 45-106. It is not an annual report, earnings release, or any other financial report but a specific regulatory disclosure related to securities distribution. The document is lengthy (15,000 characters) and contains substantive data, not just an announcement or certification. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2024-08-01 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.